Ziltivekimab targets IL-6 to effectively treat anemia patients with CKD stage 3-5, finds study
Anemia affects about 15% of CKD patients and is linked to increased morbidity, mortality, and reduced quality of life. In 30-50% of dialysis patients with kidney failure, high biomarkers of inflammation such as IL-6 and hsCRP are present. Elevated hsCRP ( …